Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.

Background Sickle cell disease ( SCD) is a worldwide distributed hereditary red cell disorder. The principal clinical manifestations of SCD are the chronic hemolytic anemia and the acute vaso-occlusive crisis ( VOCs), which are mainly characterized by ischemic/reperfusion tissue injury. Pain is the...

Descripción completa

Detalles Bibliográficos
Publicado en:Pain Practice Vol. 16; no. 6; pp. 680 - 688
Autores principales: De Franceschi, Lucia, Mura, Paolo, Schweiger, Vittorio, Vencato, Elisa, Quaglia, Francesca Maria, Delmonte, Letizia, Evangelista, Maurizio, Polati, Enrico, Olivieri, Oliviero, Finco, Gabriele
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Jul2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=116527451&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 116527451
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15307085
        HYN
      jtl: Pain Practice
      issn: 15307085
      maglogo: Y
    pubinfo:
      dt: Jul2016
      vid: 16
      iid: 6
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        116527451
        116527451
        116527451
        10.1111/papr.12313
        116527451
      ppf: 680
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
      aug:
        au:
          De Franceschi, Lucia
          Mura, Paolo
          Schweiger, Vittorio
          Vencato, Elisa
          Quaglia, Francesca Maria
          Delmonte, Letizia
          Evangelista, Maurizio
          Polati, Enrico
          Olivieri, Oliviero
          Finco, Gabriele
        affil: Department of Medicine, Section of Internal Medicine, University of Verona‐AOUI‐Verona, Verona Italy
      sug:
        subj:
          Anemia, Sickle Cell Complications
          Fentanyl Therapeutic Use
          Administration, Buccal
          Vascular Diseases Physiopathology
          Human
          Hereditary Diseases
          Anemia, Hemolytic
          Reperfusion Injury
          Pain Management
          Crossover Design
          Analgesia
          Treatment Outcomes
          Ketorolac Administration and Dosage
          Tramadol Administration and Dosage
          Fentanyl Administration and Dosage
          Patient Satisfaction
          Vasoconstriction
          Pain Drug Therapy
          Adult
          Adult: 19-44 years
      ab: Background Sickle cell disease ( SCD) is a worldwide distributed hereditary red cell disorder. The principal clinical manifestations of SCD are the chronic hemolytic anemia and the acute vaso-occlusive crisis ( VOCs), which are mainly characterized by ischemic/reperfusion tissue injury. Pain is the main symptom of VOCs, and its management is still a challenge for hematologists, requiring a multidisciplinary approach. Methods We carried out a crossover study on adult SCD patients, who received two different types of multimodal analgesia during two separate severe VOCs with time interval between VOCs of at least 6 months. The first VOC episode was treated with ketorolac (0.86 mg/kg/day) and tramadol (7.2 mg/kg/day) ( TK treatment). In the second VOC episode, fentanyl buccal tablet ( FBT; 100 μg) was introduced in a single dose after three hours from the beginning of TK analgesia ( TKF treatment). We focused on the first 24 hours of acute pain management. The primary efficacy measure was the time-weighted-sum of pain intensity differences ( SPID24). The secondary efficacy measures included the pain intensity difference ( PID), the total pain relief ( TOTPAR), and the time-wighted sum of anxiety ( SAID24). Results SPID24 was significantly higher in TKF than in TK treatment. All the secondary measures were significantly ameliorated in TKF compared to TK treatment, without major opioid side effects. Patients satisfaction was higher with TKF treatment than with TK one. Conclusions We propose that VOCs might require breakthrough pain drug strategy as vaso-occlusive phenomena and enhanced vasoconstriction promoting acute ischemic pain component exacerbate the continuous pain of VOCs. FBT might be a powerful and feasible tool in early management of acute pain during VOCs in emergency departments.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N